MystiPhage

Antibiotic resistance (ABR) is a global threat that is projected to cause over 10 million deaths per year and $100 trillion in economic losses by 2050 (UN, WHO). As this threat grows, we are running out of time to come up with a solution that puts humankind ahead. Phage therapy, which uses tiny viruses called phages to kill bacteria, represents an extremely promising pathway to help combat ABR. The key to phage therapy is in the specific way it interacts with the superbug bacteria infecting a patient. The specific way the bacteria are infected and killed can possibly be very harmful to the patient themselves; the difficulty in making therapeutic phages that don’t have these adverse effects is currently the limiting factor in phage therapy that is preventing it from saving millions of lives. To solve this, we are developing a platform that leverages generative AI to custom-make phages with the optimal infection characteristics for a given bacteria and patient. This way, we can make suitable phages for phage therapy that have no adverse effects and target bacteria with higher efficiency, which will save millions of lives. The total addressable market of antibiotic resistance worldwide is $12.50 billion USD, the serviceable addressable market in healthcare is $9.12 billion USD, and the serviceable obtainable market sits at $1.1 billion USD. All numbers are based on 2030 projections.